The Chin group researches and develops novel imaging agents and therapeutics with a focus on PET (Positron Emission Tomography) imaging.  Located within the Cyclotron and Radiochemistry Facility and associated with the Molecular Imaging Program at Stanford, we are involved in the arc of drug development all the way from research on the benchtop to translational first-in-human clinical studies, primarily using radiolabeled 18F and 11C tracers. 

Much of our interest lies in developing tracers to image the mysterious diseases of the brain (e.g., pain, addiction, Parkinson’s disease, Alzheimer’s disease, glioblastoma) or other cancers.  Frequently projects begin with the desire to image a particular target, and subsequently developing an agent that can be radiolabeled for cellular and in vivo studies.  We work closely with collaborators both within Stanford and worldwide to develop and optimize these ideas into viable tracers.

Closely linked with Stanford Health Care, the Chin group is highly motivated to bring tracers to the clinical setting.  In addition to providing more than 20 doses of 18F-FDG daily for standard-of-care PET imaging, we have brought or are in the process of bringing more than a dozen other tracers to the clinic.

Are you interested in participating in a study? There are many areas in which we are recruiting for studies. Please visit the Clinical Trials page to see the studies for which we are currently recruiting and visit Red Cap to complete a survey to express interest in brain research studies.

TRACER News

Young Investigator Award Given to Dr. Fung

Dr. Klockow Receives Young Scientist Travel Award

Dr. Klockow Earns Young Women in Science Award

SMIS Fellowship Awarded to Dr. Klockow

R21 Grant Awarded for GBM Research

Bio-X Fellowship Awarded to Undergraduate Research Assistant

Soujanya Gade Accepted to PhD program at Palo Alto University